| Molecular and clinical significance of fibroblast growth factor 2 (FGF2/bFGF) in malignancies of solid and hematological cancers for personalized therapies MR Akl, P Nagpal, NM Ayoub, B Tai, SA Prabhu, CM Capac, M Gliksman, ... Oncotarget 7 (28), 44735, 2016 | 192 | 2016 |
| Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine MR Akl, P Nagpal, NM Ayoub, SA Prabhu, M Gliksman, B Tai, A Hatipoglu, ... Oncotarget 6 (30), 28693, 2015 | 92 | 2015 |
| Inhibitory effect of genistein on the invasive potential of human cervical cancer cells via modulation of matrix metalloproteinase-9 and tissue inhibitiors of matrix … A Hussain, G Harish, SA Prabhu, J Mohsin, MA Khan, TA Rizvi, C Sharma Cancer Epidemiology 36 (6), e387-e393, 2012 | 80 | 2012 |
| Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas JK Lue, SA Prabhu, Y Liu, Y Gonzalez, A Verma, PS Mundi, NA Abshiru, ... Clinical Cancer Research, clincanres. 3989.2018, 2019 | 72 | 2019 |
| Sulforaphane inhibits growth of human breast cancer cells and augments the therapeutic index of the chemotherapeutic drug, gemcitabine A Hussain, J Mohsin, SA Prabhu, S Begum, QEA Nusri, G Harish, E Javed, ... Asian Pacific Journal of Cancer Prevention 14 (10), 5855, 2013 | 46 | 2013 |
| The MNK1/2-eIF4E axis as a potential therapeutic target in melanoma SA Prabhu, O Moussa, WH Miller Jr, SV Del Rincón International Journal of Molecular Sciences 21 (11), 4055, 2020 | 27 | 2020 |
| Mechanisms of acquired drug resistance to the HDAC6 selective inhibitor ricolinostat reveals rational drug-drug combination with ibrutinib JE Amengual, SA Prabhu, M Lombardo, K Zullo, PM Johannet, ... Clinical cancer research 23 (12), 3084-3096, 2017 | 26 | 2017 |
| MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression W Yang, E Khoury, Q Guo, SA Prabhu, A Emond, F Huang, C Gonçalves, ... Oncogene 39 (18), 3650-3665, 2020 | 21 | 2020 |
| Mono-and bi-cyanoacrylic acid substituted phenothiazine based sensitizers for dye sensitized solar cells E Kavery, S Muruganantham, S Prabhu, R Renganathan, SY Chin, ... Optik 208, 164046, 2020 | 15 | 2020 |
| Nusri Qel A, Harish G, Javed E, Khan MA, Sharma C. Sulforaphane inhibits growth of human breast cancer cells and augments the therapeutic index of the chemotherapeutic drug … A Hussain, J Mohsin, SA Prabhu, S Begum Asian Pac J Cancer Prev 14, 5855-5860, 2013 | 11 | 2013 |
| Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance MS Dahabieh, F Huang, C Goncalves, RE Flores González, S Prabhu, ... Autophagy 18 (3), 540-558, 2022 | 10 | 2022 |
| Molecular and clinical significance of fibroblast growth factor 2 (FGF2/bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016; 7 … MR Akl, P Nagpal, NM Ayoub, B Tai, SA Prabhu, CM Capac, M Gliksman, ... Epub 2016/03/24. doi: 10.18632/oncotarget. 8203. PubMed PMID: 27007053, 0 | 9 | |
| A Combined Experimental and Theoretical Investigation of Perylene Based Dyes as Sensitizer for Dye-Sensitized Solar Cell E Kavery, G Vinodha, S Prabhu, R Renganathan, CS Yee, MMR Khan Russian Journal of Physical Chemistry B 15, S92-S101, 2021 | 6 | 2021 |
| Dual inhibition of EZH2 and HDAC is synergistic in EZH2 Dysregulated Lymphomas JK Lue, SA Prabhu, Y Liu, A Verma, O Elemento, JE Amengual Hematological Oncology 35, 254-255, 2017 | 6 | 2017 |
| Epigenetic targeting with EZH2 and HDAC inhibitors is synergistic in EZH2 deregulated lymphomas JK Lue, SA Prabhu, Y Liu, OA O'Connor, JE Amengual Blood 128 (22), 839, 2016 | 5 | 2016 |
| Molecular and clinical significance of fibroblast growth factor 2 (FGF2/bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 7 … MR Akl, P Nagpal, NM Ayoub, B Tai, SA Prabhu, CM Capac, M Gliksman, ... | 5 | 2016 |
| Nusri Qel A, Harish G, Javed E, Khan MA, Sharma C. 2013. Sulforaphane inhibits growth of human breast cancer cells and augments the therapeutic index of the chemotherapeutic … A Hussain, J Mohsin, SA Prabhu, S Begum Asian Pac J Cancer Prev 14, 5855-5860, 0 | 2 | |
| Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer SA Prabhu, O Moussa, C Gonçalves, JH LaPierre, H Chou, F Huang, ... Molecular Cancer Therapeutics 22 (2), 192-204, 2023 | 1 | 2023 |
| High Expression of FGF2/SDC1 Signaling Contributes to Poor Clinical Outcome in Hodgkin Lymphoma Patients and SDC1 siRNA Suppresses Proliferation, Migration, and Invasion in … P Nagpal, A Goy, A Gangadharan, MR Akl, I Voznenko, M Soni, B Tai, ... Blood 130, 1483, 2017 | 1 | 2017 |
| Mechanisms of acquired drug resistance to the isoform selective HDAC6 inhibitor ricolinostat reveals markedly upregulated elements of the BTK pathway revealing rational drug … JE Amengual, M Lombardo, KM Zullo, PM Johannet, SA Prabhu, ... Blood 126 (23), 3708, 2015 | 1 | 2015 |
